news.today
Hello · Register today | LoginHello · My Account[—] [32]
Business

Israeli prenatal screening firm lists on Australian exchange

Summarised from 2 outlets · Updated 13 Oct, 05:02 · Archive

Identifai Genetics, an Israeli company developing an AI-powered prenatal blood test, has listed on Australia's stock exchange with shares up 20 per cent on debut.

Identifai Genetics, an Israeli company developing an artificial intelligence-powered prenatal screening test, has successfully listed on Australia's stock exchange. Shares opened at 24 cents on Tuesday afternoon, up 20 per cent from the 20-cent initial public offering price, giving the company a market cap of $21.8 million. Chief executive Eyal Miller said the market's response had been gratifying.

The $10 million raised in the IPO will fund development of the Windrose test, a blood test for pregnant women at least nine weeks along. The test uses genomic sequencing and AI to analyse cell-free DNA from the mother and foetus to predict selected inherited conditions. According to Identifai, nearly 300 genes are relevant to prenatal diagnosis and 54 genetic conditions are treatable in the womb.

Miller said the test can examine the entire genome, unlike existing non-invasive prenatal tests (NIPT) available since 2011, which screen only for Down syndrome and a few other conditions. The Windrose test is based on work by Tel Aviv University scientists Professor Noam Shomron and Dr Tom Rabinowitz. The company is currently validating the test through a 600-patient clinical trial.

Israeli prenatal screening firm lists on Australian exchange
Image: Perth Now

Comments (0)

How it is being reported

In this story: Identifai Genetics · Australia · Eyal Miller · Noam Shomron · Tom Rabinowitz · Tel Aviv University

This summary was written by AI from the headlines and standfirsts above, and states as fact only what at least two outlets report. How we use AI · Report a problem